According to the World Health Organisation (“WHO”), half of population aged over 50 suffered from Osteoarthritis (“OA”), and about 80% for those aged over 55. In 1999, WHO identified OA、cancer and cardiovascular diseases as the three major killing diseases. According JSD Medicine Information (金思得醫藥資訊), total spending on OA amounted approximately 700-800 million RMB in the PRC.
Currently, more than 2 hundred million people in the world are suffering from Osteoporosis ("OP"). One third of female aged over 50 who had bone fractured were caused by OP. It is estimated that 640 million people would suffer from bone fracture by 2050.
It is estimated that there are 90 million people suffering from original OP and 100 million people suffering from secondary OP in China. Survey indicated sales of a very effective drug on OP, Calcitonin, has reached RMB 100 million in 16 major PRC cities in 2004; and the number is continuously increasing.
The group has earned its reputation with its prime product, Triamcinolone Acetonide Injection (同息通, “Tong Xitong”), a long acting steroid for osteo-arthritis and rheumatoid arthritis. In June 2004, the Group also started to act as the sole agent and put on the PRC market a branded Calcitonin for injection by Lisapharma SpA, a renowned Italian pharmaceutical company.
Riding on its success, the group is currently developing two new products in this category: Risedronate Sodium Tablets (the latest biphosphate for osteoporosis), and Hydrocortisone Sodium Succinate for Injection; the group is also appointed by Trans Bussan from Switzerland as the sole agent for its worldwide patented new drug, Diacerein Capsules (Atrodar), in the PRC.
Triamcinolone Acetonide Injection (同息通, “Tong Xitong”)
Triamcinolone Acetonide can produce powerful and prolonged anti-inflammation and anti-allergy effect, which makes it an ideal medicine for rheumatic and rheumatoid arthritis. The group’s own brand, 同息通 (Tong Xitong), was awarded “Yunnan Famous Brand Award” in 2003 and “ Yunnan top 30 Famous Brand” in 2004.